| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis |
|
Medicine details |
|
| Medicine name | rituximab (MabThera®) |
| Formulation | 100 mg, 500mg concentrate for solution for infusion |
| Reference number | 1521 |
| Indication | In combination with glucocorticoids, for the induction of remission in adult patients with severe, active granulomatosis with polyangiitis (Wegener’s) (GPA) and microscopic polyangiitis (MPA) |
| Company | Roche Products Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 31/05/2013 |
| NICE guidance | |